Purines

2021 Update Bulletin on Multiple Sclerosis - Ocrevus Has Been Approved by the European Commission - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Health, General Health, Health sciences, Health, Cladribine, Organochlorides, Purines, Ocrelizumab, Multiple sclerosis

The "Multiple Sclerosis: Update Bulletin" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Sclerosis: Update Bulletin" newsletter has been added to ResearchAndMarkets.com's offering.
  • This report presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market.
  • Which agents are anticipated to lose market share as a result of Ocrevus' launch?
  • How do KOLs view Mavenclad, and how successful has the European launch been?

Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform

Retrieved on: 
Wednesday, July 14, 2021
Drugs, Psychoactive drugs, Analgesics, Purines, Adenosine, Nucleosides, Vasodilators, Pain management, Paracetamol, Ketamine

Dr. Robert D. Thompson, Adials Vice President, Chemistry, commented, We are highly encouraged by the latest preclinical data related to our adenosine platform as a potential therapy for pain relief.

Key Points: 
  • Dr. Robert D. Thompson, Adials Vice President, Chemistry, commented, We are highly encouraged by the latest preclinical data related to our adenosine platform as a potential therapy for pain relief.
  • Importantly, our latest solubility data may be the key to unlocking the potential of adenosine analogs as a therapy.
  • Also noteworthy, we studied our adenosine compounds in combination with Tylenol and demonstrated enhanced pain reduction and duration of pain relief in vivo.
  • Purnovate, Inc., a division of Adial Pharmaceuticals, is developing adenosine analogs for the treatment of pain and other disorders.

Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements

Retrieved on: 
Monday, July 12, 2021
Research, Diabetes, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Medical specialties, Hepatitis, Branches of biology, Clinical medicine, Adenosine monophosphate, Neurotransmitters, Nucleotides, Purines, Steatohepatitis, Non-alcoholic fatty liver disease, NASH, ALD, Poxel SA, NASH, ALD, POXEL SA

Following our recent achievements and a thorough review of the Companys programs, we are excited to announce a new strategic direction for Poxel, with an increasing focus on rare metabolic indications that represents the intersection of high unmet medical needs, promising pre-clinical and clinical data, opinion leader enthusiasm, significant commercial opportunity, and attractive time horizons.

Key Points: 
  • Following our recent achievements and a thorough review of the Companys programs, we are excited to announce a new strategic direction for Poxel, with an increasing focus on rare metabolic indications that represents the intersection of high unmet medical needs, promising pre-clinical and clinical data, opinion leader enthusiasm, significant commercial opportunity, and attractive time horizons.
  • In parallel with the Companys efforts in ALD, another important goal is to launch an additional rare disease development program in 2022.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.
  • Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.

DGAP-News: AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of HSV infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Retrieved on: 
Thursday, July 8, 2021
Chemical compounds, Purines, Organic compounds, Foscarnet, Aciclovir, Chemistry, pritelivir, HSV, AiCuris Anti-infective Cures AG, PRITELIVIR, HSV, AICURIS ANTI-INFECTIVE CURES AG

The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

Key Points: 
  • The PRIOH-1 multi-center open label trial is designed to evaluate the efficacy and safety of orally administered pritelivir for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
  • Efficacy was also seen in patients who in addition showed resistance or intolerance to foscarnet and had very limited treatment options.
  • In none of the patients, treatment with pritelivir was prematurely discontinued due to adverse events during the trial.
  • Based on the results from the recent US clinical phase 2 trial, AiCuris has started a pivotal phase 3 trial as a basis for NDA submission.

Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection

Retrieved on: 
Tuesday, June 29, 2021
Medical specialties, Health, Arbutus Biopharma, Gilead Sciences, Hepatotoxins, Infectious causes of cancer, Purines, ABUS, Hepatitis B, Reverse-transcriptase inhibitor, Tenofovir disoproxil, Hepatitis

ATI-2173, AB-729 and Viread will be evaluated in combination in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial.

Key Points: 
  • ATI-2173, AB-729 and Viread will be evaluated in combination in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial.
  • Our collaboration with Arbutus will test that hypothesis in combination with AB-729, an RNAi drug candidate, and Viread, a nucleotide analogue.
  • The combination clinical trial cohort will include 10 subjects with chronic HBV infection assigned 8:2 to active drug (ATI-2173+AB-729) or matching placebos.
  • Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.

CBMG Holdings Announces Data from Two CAR-T Clinical Studies Selected for Podium Presentations at ASCO Annual Meeting

Retrieved on: 
Tuesday, June 1, 2021
Clinical medicine, Cancer treatments, Drugs, Arabinosides, Fludarabine, Organofluorides, Organophosphates, Purines, Cyclophosphamide, Chimeric antigen receptor T cell, Cancer immunotherapy, Oncology

GMP manufacture of C-CAR066 was in a serum free and fully closed semi-automatic system.

Key Points: 
  • GMP manufacture of C-CAR066 was in a serum free and fully closed semi-automatic system.
  • A 3-day cyclophosphamide plus fludarabine regimen was followed by a single infusion of C-CAR066.
  • C-CAR066 has shown a favorable safety profile and promising efficacy in patients with r/r B-NHL following failure of CD19 CAR-T therapy.
  • The company conducts immuno-oncology and stem cell clinical trials inChinausing products from its integrated GMP laboratory.

Global Adenosine Triphosphate Swab Test Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Health, Pharmaceutical, Medical specialties, Adenosine, Nucleosides, Purines, Vasodilators, ATP, Clinical medicine, Drugs

The "Adenosine Triphosphate Swab Test Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adenosine Triphosphate Swab Test Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to ResearchAndMarkets.com's offering.
  • The adenosine triphosphate (ATP) swab test market was valued at US$ 198.21 million in 2019 and is projected to reach US$ 369.71 million by 2027; it is expected to grow at a CAGR of 8.10% from 2019 to 2027.
  • The implementation of safety measures to prevent the spread of COVID-19 is driving the adoption of adenosine triphosphate (ATP) swabs.
  • Moreover, the major shift in focus toward microbial safety amid the pandemic is offering lucrative opportunities for the growth of the market players.

Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Pharmaceutical, Publishing, Oncology, Health, TV and Radio, Communications, Entertainment, Purines, Medical specialties, Adenosine, Nucleosides, Vasodilators, Binding selectivity, Clinical medicine, Drugs, Piclidenoson, Namodenoson, Can-Fite BioPharma Ltd., PICLIDENOSON, NAMODENOSON, CAN-FITE BIOPHARMA LTD.

In the exclusive interview, Dr. Fishman discusses the Companys upcoming milestones, updates on the pipeline of proprietary small molecule drugs addressing inflammatory, cancer and liver diseases.

Key Points: 
  • In the exclusive interview, Dr. Fishman discusses the Companys upcoming milestones, updates on the pipeline of proprietary small molecule drugs addressing inflammatory, cancer and liver diseases.
  • To view the interview segment, please visit: https://youtu.be/WVxnEwJ8WXo
    The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
  • Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR).
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

2021 Global Zeatin (CAS 1637-39-4) Market Report - Key Manufacturers and Distributors - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Chemicals, Plastics, Manufacturing, Cytokinins, Purines, Zeatin, Business process, Market research

b'The "Zeatin (CAS 1637-39-4) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Zeatin.

Key Points: 
  • b'The "Zeatin (CAS 1637-39-4) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Zeatin.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.\nThe Zeatin global market report key points:\n'

EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

Retrieved on: 
Friday, April 23, 2021
Health, Infectious diseases, Clinical trials, General Health, Pharmaceutical, Biotechnology, Orphan drugs, Cladribine, Organochlorides, Purines, Health, COVID-19

The safety database analysis included cases of confirmed (n=160) or suspected (n=101) COVID-19 in MAVENCLAD-treated patients.

Key Points: 
  • The safety database analysis included cases of confirmed (n=160) or suspected (n=101) COVID-19 in MAVENCLAD-treated patients.
  • Based on the analysis, the majority of patients had mild to moderate respiratory symptoms and none required mechanical ventilation.
  • After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years.
  • Women who become pregnant during treatment with MAVENCLAD should discontinue treatment.\nLymphopenia: MAVENCLAD causes a dose-dependent reduction in lymphocyte count.